CLL: New DevelopmentsFarrukh Awan
EP: 1.Current Front-Line Treatment Options for CLL in 2023 EP: 2.Exploring BTKi Monotherapy in CLL: Long-Term Updates from ELEVATE-TN and SEQUOIA EP: 3.Strategies for Managing Treatment-Naïve CLL with High-Risk Features EP: 4.Impact of Off-Target AEs and Treatment Resistance on Evolving...
Standard treatment approaches for patients with chronic lymphocytic leukemia (CLL) will continue to include fludarabine, cyclophosphamide, and rituximab (FCR) and allogeneic stem cell transplantation. However, recent approvals of novel agents and ongoing developments of combination regimens are advancing the...
EP: 1.Introducing the Expert Panel on CLL Treatment Updates Live at EHA 2024 EP: 2.Testing Practices and Role of High-risk Features to Decision Making in Newly Diagnosed CLL EP: 3.Frontline BTKi Selection EP: 4.Dr Parrondo’s Frontline CLL...
Patients with chronic lymphocytic leukemia who stopped treatment with ibrutinib (Imbruvica) for toxicities had longer survival than those who discontinued for other reasons, including progression and Richter transformation.
Based on promising findings, the BTK inhibitor ibrutinib gained accelerated approval as a treatment for patients with CLL and mantle cell lymphoma (MCL).Ibrutinib is very active in both CLL and MCL, with very long remission duration demonstrated in clinical trials. The major question that still ...
In this case, the decision will be based not on efficacy directly, because those agents are effective, but on the patient preference: for example, fixed duration vs a continuous treatment. On the other side, all the comorbidities of the patient that might suggest 1 treatment better is than ...
On March 14, 2024, the FDA granted accelerated approval to liso-cel for the treatment of adult patients with relapsed/refractory CLL or SLL who have been treated with 2 or more prior lines of therapy, including a BCL-2 inhibitor and a BTK inhibitor. This regulatory decision was suppo...
With the rise of novel agents and several regulatory approvals, treatment for patients with chronic lymphocytic leukemia (CLL) continues to shift away from the use of chemoimmunotherapy, according to Matthew S. Davids, MD, MMSc, who added that, to date, chemoimmunotherapy is only used in a ...
Venetoclax is approved in the United States for the treatment of patients with CLL who have relapsed/refractory disease and 17p deletion, but some of us in the field are using it off label. Now that we have the MURANO trial data from the 2017 ASH Annual Meeting, we know that the ...